Argentina - Drug Information Association
Argentina - Drug Information Association
Argentina - Drug Information Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
European Union - EMA/769460/2010 - P/315/2010: Decision on the Application<br />
for Agreement of a Paediatric Investigation Plan for Modified allergen extract of<br />
grass pollen, 22-Dec-2010<br />
The Paediatric Committee has given a positive opinion for a request for agreement of Paediatric Investigation Plan for the<br />
active substance Modified allergen extract of grass pollen. - Applicant: ROXALL Medizin GmbH. - Conditions: Treatment of<br />
allergic rhinitis / rhino-conjunctivitis. - Pharmaceutical form: Suspension for injection. - Route of administration:<br />
Subcutaneous use. More detailed information regarding the Paediatric Investigation Plan (PIP): - Proposed PIP indication:<br />
For the subcutaneous treatment of allergic rhinitis / rhino-conjunctivitis due to pollen of the group of sweet grasses of the<br />
Poaceae (Gramineae) family. - Age subset: From 5 years to less than 18 years of age. - Date of completion of the PIP: By<br />
October 2026. - Deferral: Yes.<br />
Document date: 22-Dec-2010<br />
Type of text: Opinion, PDCO Opinion<br />
Regulatory version: None<br />
Language: English<br />
European Union - EMA/778420/2010 - P/329/2010: Decision on the Application<br />
for Agreement of a Paediatric Investigation Plan for Aqueous allergen extract of<br />
birch, alder and hazel pollen, 22-Dec-2010<br />
The Paediatric Committee has given a positive opinion for a request for agreement of Paediatric Investigation Plan for the<br />
active substance Aqueous allergen extract of birch, alder and hazel pollen. - Applicant: ROXALL Medizin GmbH. - Conditions:<br />
Treatment of allergic rhinitis / rhino-conjunctivitis. - Pharmaceutical form: Oral solution. - Route of administration:<br />
Sublingual use. More detailed information regarding the Paediatric Investigation Plan (PIP): - Proposed PIP indication:<br />
Treatment of allergic rhinitis / rhino-conjunctivitis due to tree pollen of the birch group. - Age subset: From 5 years to less<br />
than 18 years of age. - Date of completion of the PIP: By October 2025. - Deferral: Yes.<br />
Document date: 22-Dec-2010<br />
Type of text: Opinion, PDCO Opinion<br />
Regulatory version: None<br />
Language: English<br />
European Union - EMA/800116/2010 - P/339/2010: Decision on the Application<br />
for Agreement of a Paediatric Investigation Plan for Modified allergen extract of<br />
Dermatophagoides pteronyssinus and Dermatophagoides farinae, 22-Dec-2010<br />
The Paediatric Committee has given a Positive Opinion for a request for agreement of Paediatric Investigation Plan for the<br />
active substance Modified allergen extract of Dermatophagoides pteronyssinus and Dermatophagoides farinae. - Applicant:<br />
ROXALL Medizin GmbH - Condition: Treatment of allergic rhinitis/rhino-conjunctivitis - Pharmaceutical form: Suspension for<br />
injection - Route of administration: Subcutaneous use More detailed information regarding the Paediatric Investigation Plan<br />
(PIP): - Proposed PIP indication: Treatment of allergic rhinitis/rhino-conjunctivitis due to house dust mite allergens. - Age<br />
subset: From 5 to less than 18 years of age. - Date of completion of the PIP: By September 2025 - Deferral: Yes<br />
Document date: 22-Dec-2010<br />
Type of text: Opinion, PDCO Opinion<br />
Regulatory version: None<br />
Language: English<br />
European Union - EMA/801965/2010 - P/342/2010: Decision on the Application<br />
for Agreement of a Paediatric Investigation Plan for Modified allergen extract of<br />
dermatophagoides pteronyssinus and dermatophagoides farinae, 22-Dec-2010<br />
The Paediatric Committee has given a Positive Opinion for a request for agreement of Paediatric Investigation Plan for the<br />
active substance Modified allergen extract of dermatophagoides pteronyssinus and dermatophagoides farinae. - Applicant:<br />
ROXALL Medizin GmbH - Condition: Treatment of allergic rhinitis/rhino-conjunctivitis - Pharmaceutical form: Suspension for<br />
injection - Route of administration: Subcutaneous use More detailed information regarding the Paediatric Investigation Plan<br />
(PIP): - Proposed PIP indication: Treatment of allergic rhinitis/rhino-conjunctivitis due to house dust mite allergens. - Age<br />
subset: From 5 to less than 18 years of age. - Date of completion of the PIP: By September 2027 - Deferral: Yes<br />
Document date: 22-Dec-2010<br />
Type of text: Opinion, PDCO Opinion<br />
Regulatory version: None<br />
Language: English<br />
European Union - EMA/802042/2010 - P/341/2010: Decision on the Application<br />
for Agreement of a Paediatric Investigation Plan for Modified allergen extract of<br />
dermatophagoides farinae, 22-Dec-2010<br />
The Paediatric Committee has given a Positive Opinion for a request for agreement of Paediatric Investigation Plan for the